Suppr超能文献

透析方式与死亡率之间的关系。

Relationship between dialysis modality and mortality.

作者信息

McDonald Stephen P, Marshall Mark R, Johnson David W, Polkinghorne Kevan R

机构信息

Renal Unit, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South SA 5011, Australia.

出版信息

J Am Soc Nephrol. 2009 Jan;20(1):155-63. doi: 10.1681/ASN.2007111188. Epub 2008 Dec 17.

Abstract

Mortality differences between peritoneal dialysis (PD) and hemodialysis (HD) are widely debated. In this study, mortality was compared between patients treated with PD and HD (including home HD) using data from 27,015 patients in the Australia and New Zealand Dialysis and Transplant Registry, 25,287 of whom were still receiving PD or HD 90 d after entry into the registry. Overall mortality rates were significantly lower during the 90- to 365-d period among those being treated with PD at day 90 (adjusted hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.81 to 0.99]; P < 0.001). This effect, however, varied in direction and size with the presence of comorbidities: Younger patients without comorbidities had a mortality advantage with PD treatment, but other groups did not. After 12 mo, the use of PD at day 90 was associated with significantly increased mortality (adjusted HR 1.33; 95% CI 1.24 to 1.42; P < 0.001). In a supplementary as-treated analysis, PD treatment was associated with lower mortality during the first 90 d (adjusted HR 0.67; 95% CI 0.56 to 0.81; P < 0.001). These data suggest that the effect of dialysis modality on survival for an individual depends on time, age, and presence of comorbidities. Treatment with PD may be advantageous initially but may be associated with higher mortality after 12 mo.

摘要

腹膜透析(PD)和血液透析(HD)之间的死亡率差异存在广泛争议。在本研究中,利用澳大利亚和新西兰透析与移植登记处27015例患者的数据,比较了接受PD和HD(包括家庭血液透析)治疗患者的死亡率,其中25287例在进入登记处90天后仍在接受PD或HD治疗。在第90天接受PD治疗的患者中,90至365天期间的总体死亡率显著较低(调整后风险比[HR]0.89;95%置信区间[CI]0.81至0.99;P<0.001)。然而,这种效应会因合并症的存在而在方向和大小上有所不同:无合并症的年轻患者接受PD治疗有死亡率优势,但其他组则没有。12个月后,第90天使用PD与死亡率显著增加相关(调整后HR 1.33;95%CI 1.24至1.42;P<·0.001)。在一项补充的实际治疗分析中,PD治疗在最初90天内与较低死亡率相关(调整后HR 0.67;95%CI 0.56至0.81;P<0.001)。这些数据表明,透析方式对个体生存的影响取决于时间、年龄和合并症的存在。PD治疗最初可能具有优势,但12个月后可能与较高死亡率相关。

相似文献

1
Relationship between dialysis modality and mortality.透析方式与死亡率之间的关系。
J Am Soc Nephrol. 2009 Jan;20(1):155-63. doi: 10.1681/ASN.2007111188. Epub 2008 Dec 17.
5
Dialysis Modality and Mortality in the Elderly: A Meta-Analysis.老年患者的透析方式与死亡率:一项荟萃分析
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):983-93. doi: 10.2215/CJN.05160514. Epub 2015 May 4.

引用本文的文献

8
Peritoneal dialysis versus haemodialysis for people commencing dialysis.腹膜透析与血液透析治疗开始透析的患者。
Cochrane Database Syst Rev. 2024 Jun 20;6(6):CD013800. doi: 10.1002/14651858.CD013800.pub2.
10
Home versus in-centre haemodialysis for people with kidney failure.居家透析与中心透析治疗肾衰竭患者的效果比较。
Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD009535. doi: 10.1002/14651858.CD009535.pub3.

本文引用的文献

6
Variable selection for propensity score models.倾向得分模型的变量选择
Am J Epidemiol. 2006 Jun 15;163(12):1149-56. doi: 10.1093/aje/kwj149. Epub 2006 Apr 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验